University of Illinois Cancer Center | Strategic Alliance Partners

Oncology practices across the United States have rapidly increased telehealth use in 2020 to mitigate the risk of coronavirus disease 2019 (COVID-19) to patients with cancer who are at particular risk of complications.

Sandra Cuellar, PharmD, BCOP, discusses challenges with ​data extrapolation for biosimilars. 

Lawrence E. Feldman, MD, discusses utilizing prophylactic cranial irradiation in limited-stage and extensive-stage small cell lung cancer.

Lawrence E. Feldman, MD, discusses exciting new data surrounding immunotherapy combinations in lung cancer.

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.

Given the "addiction" of many tumors to mutant RAS for their survival, there has been renewed interest in developing new ways to inhibit RAS in cancer.